Aastha Oncology Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 04-07-2024
- Paid Up Capital ₹ 5.00 M
as on 04-07-2024
- Company Age 17 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 16.65%
(FY 2023)
- Profit -13.06%
(FY 2023)
- Ebitda -9.60%
(FY 2023)
- Net Worth 18.10%
(FY 2023)
- Total Assets 15.61%
(FY 2023)
About Aastha Oncology
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M, as per Ministry of Corporate Affairs (MCA) records.
Vijay Devanhalli, Rajendra Toprani, Jagdishbhai Kothari, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110GJ2007PTC051327
- Company No.
051327
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jul 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aastha Oncology?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaustubhbhai Patel  | Director | 16-Jul-2007 | Current |
| Vijay Devanhalli | Director | 17-Jul-2007 | Current |
| Rajendra Toprani | Director | 17-Jul-2007 | Current |
| Jagdishbhai Kothari | Director | 16-Jul-2007 | Current |
Financial Performance and Corporate Structure Insights of Aastha Oncology.
Aastha Oncology Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.65% increase. The company also saw a substantial fall in profitability, with a 13.06% decrease in profit. The company's net worth Soared by an impressive increase of 18.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aastha Oncology?
In 2023, Aastha Oncology had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hcg Medi-Surge Hospitals Private LimitedActive 24 years 9 monthsVijay Devanhalli, Rajendra Toprani and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aastha Oncology?
Unlock and access historical data on people associated with Aastha Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aastha Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aastha Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
